First slide

FUJIFILM Corporation to meet the accelerate demand of consumers, announced to invest $850 million in its core Bio CDMO subsidiary, FUJIFILM Diosynth Biotechnologies. The investments will strength FUJIFILMÂ’s contract development and manufacturing to increase capacity.

  • FUJIFILM Diosynth Biotechnologies is an industry-leading biologics Contract Development and Manufacturing Organization (CDMO) with experience in the development and manufacturing of recombinant proteins, vaccines, monoclonal antibodies, among other large molecules and viral products expressed in a wide array of microbial, mammalian, and host/virus systems.
  • The expansions will double cell culture production for recombinant vaccines in the United States.

The major acquisitions and expansions by FUJIFILM in are mentioned below:

Oct 2020: The global biotechnology leader FUJIFILM Corporation announced the expansion of its gene therapy services, with the addition of viral vector process development and GMP manufacturing services at FUJIFILM Diosynth Biotechnologies’ in the North East of the United Kingdom(UK).

June 2020: The global imaging and CDMO leader FUJIFILM Corporation announced a capital investment of approximately $928 million in the Denmark site of FUJIFILM Diosynth Biotechnologies. The investments will double the Denmark site’s drug substance manufacturing capacity.

May 2020: The global imaging and CDMO leader FUJIFILM Corporation announced a capital investment of approximately $928 million in the Denmark site of FUJIFILM Diosynth Biotechnologies. The investments will double the Denmark site’s drug substance manufacturing capacity.

April 2020: North Carolina based FUJIFILM Diosynth Biotechnologies (FDB) announced a strategic partnership with OXGENE, an industry leader in the design and development of gene therapy technologies. is a leading cGMP Contract Development and Manufacturing Organization (CDMO ). It has licensed OXGENE’s proprietary AAV system for commercial use, to support biotech companies engaged in gene therapy development and manufacture.

March 2020: The global biologics Contract Development and Manufacturing Organization (CDMO) FUJIFILM Diosynth Biotechnologies (FDB), announced the construction of a new BioCampus at its Billingham, UK location. FDB is supporting the biopharmaceutical industry with the development and production of biologics, vaccines and gene therapies.

About FUJIFILM
Fujifilm, headquartered in Tokyo, Japan, is a leading photography and imaging company. It started in 1934 as a photographic film maker, and now the company has a global presence for innovation in healthcare, optical devices, graphic arts, highly functional materials, and other high-tech areas.

Related News